# Cannabis Beverage Product Development Trends in 2026 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-beverage-product-development-2026/ > **Published:** 2026-04-01T09:25:33-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:32:58-04:00 > **Clinical Summary:** Explore cannabis beverage product development and regulatory trends shaping the 2026 market landscape for clinicians and industry watchers. --- In the Mix — Last 24 HoursApril 01, 2026. 7 articles reviewed below the CED clinical relevance threshold of 35. Listed in descending order of score. #25 [Intellectual Property Considerations For Cannabis And Hemp Industry Executives – Mondaq](https://www.mondaq.com/unitedstates/cannabis/1767246/intellectual-property-considerations-for-cannabis-and-hemp-industry-executives) This article addresses intellectual property strategies for [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) business operations, which may interest clinicians tracking regulatory and commercial developments affecting product availability and market structure. [Read more →](https://www.mondaq.com/unitedstates/cannabis/1767246/intellectual-property-considerations-for-cannabis-and-hemp-industry-executives) #15 [Kick Fizz’s Evening Buzz Is Named Best THC–CBD Drink of 2026 – Food & Wine](https://www.foodandwine.com/kick-fizz-evening-buzz-best-cbd-thc-beverage-wswa-wine-and-spirits-tasting-competition-2026-11938377) A cannabis-infused beverage product received awards at a 2026 spirits competition, potentially relevant to clinicians monitoring commercial cannabinoid product development and market trends. [Read more →](https://www.foodandwine.com/kick-fizz-evening-buzz-best-cbd-thc-beverage-wswa-wine-and-spirits-tasting-competition-2026-11938377) #15 [The Real Cornbread Hemp launches THC beverages in Kentucky – The Courier-Journal](https://www.courier-journal.com/story/money/companies/2026/04/01/the-real-cornbread-hemp-launches-thc-beverages-in-kentucky/89248016007/) A former cannabis cultivator launches THC beverages in Kentucky, illustrating market expansion and branding disputes within the emerging legal cannabis beverage sector. [Read more →](https://www.courier-journal.com/story/money/companies/2026/04/01/the-real-cornbread-hemp-launches-thc-beverages-in-kentucky/89248016007/) #15 [New Hampshire House Passes Scaled-Back Psilocybin Bill, While Rejecting Measure To …](https://www.marijuanamoment.net/new-hampshire-house-passes-scaled-back-psilocybin-bill-while-rejecting-measure-to-protect-medical-marijuana-patients-gun-rights/) New Hampshire legislators advanced psilocybin policy discussion through an advisory board bill, demonstrating regulatory precedent potentially relevant to clinicians monitoring psychedelic and cannabis policy convergence. [Read more →](https://www.marijuanamoment.net/new-hampshire-house-passes-scaled-back-psilocybin-bill-while-rejecting-measure-to-protect-medical-marijuana-patients-gun-rights/) #15 [5 Best Marijuana Stocks to Buy Right Now – Insider Monkey](https://www.insidermonkey.com/blog/5-best-marijuana-stocks-to-buy-right-now-1729178/) This article lists publicly traded cannabis companies, which may interest clinicians tracking industry developments and potential funding sources for [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) initiatives. [Read more →](https://www.insidermonkey.com/blog/5-best-marijuana-stocks-to-buy-right-now-1729178/) #15 [Joyce Myers CBD Gummies: A Practical Look at the Claims for Wellness and Metabolic Support](https://www.qsr.mlit.go.jp/kikuti/pannellum/pannellum.htm?config=/%5C/ccc1.sbs/article/cbd2/0flYO9) This article examines CBD gummies as a delivery method and discusses claimed wellness and metabolic effects, which may interest clinicians tracking consumer product claims and dosing practices. [Read more →](https://www.qsr.mlit.go.jp/kikuti/pannellum/pannellum.htm?config=/%5C/ccc1.sbs/article/cbd2/0flYO9) #15 [Man fails to stop extradition to Northern Ireland on cannabis ‘growhouse’ charges](https://www.irishtimes.com/crime-law/courts/2026/04/01/man-fails-to-stop-extradition-to-northern-ireland-on-cannabis-growhouse-charges/) A man faces extradition to Northern Ireland for alleged [cannabis cultivation](https://cedclinic.com/growing-medical-marijuana-at-home-guide/) charges, illustrating jurisdictional enforcement of cannabis production laws relevant to public health and legal framework discussions. [Read more →](https://www.irishtimes.com/crime-law/courts/2026/04/01/man-fails-to-stop-extradition-to-northern-ireland-on-cannabis-growhouse-charges/) Digest-Level Clinical Commentary Dr. Caplan’s Take These digest items reveal a field experiencing rapid commercialization and market expansion alongside persistent legal fragmentation that complicates evidence-based clinical practice. The proliferation of branded THC and CBD consumer products, investment activity, and regulatory experimentation suggests patients will increasingly encounter cannabis preparations outside medical supervision, yet the clinical evidence base for most of these products remains limited and their standardization questionable. As a physician, I’m observing a disconnect between market momentum and the rigorous pharmacological data needed to responsibly counsel patients on safety, efficacy, and dosing—a gap that underscores the necessity for more [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and clearer medical-legal frameworks before cannabis becomes a reliably prescribable therapeutic. Clinical Perspective The digest reflects a maturing cannabis market characterized by product diversification beyond traditional consumption methods, particularly into regulated beverage formats, alongside continued legal and regulatory fragmentation across jurisdictions. Clinical and regulatory attention is expanding beyond cannabis itself to related compounds such as psilocybin, suggesting broader therapeutic interest in psychoactive substances. These developments underscore ongoing tension between commercial innovation and enforcement, with intellectual property and regulatory compliance remaining significant operational challenges for industry participants. Cannabis BeveragesPolicy & Regulation[Cannabis Industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/)Hemp Products 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+In+the+Mix+%E2%80%94+April+01%2C+2026+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+In+the+Mix+%E2%80%94+April+01%2C+2026+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [In the Mix: 9 More Articles — March 18, 2026](https://cedclinic.com/cannabinoid-study-depression-anxiety-ptsd/) - [In the Mix: 5 More Articles — March 14, 2026](https://cedclinic.com/medical-cannabis-dispensary-access-expansion-2026/) - [In the Mix: 31 More Articles — March 04, 2026](https://cedclinic.com/cannabis-articles-clinical-relevance-march-04-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis News Mix: June 2026 Law Enforcement and Industry Updates](https://cedclinic.com/cannabis-news-mix-june-2026-clinical-commentary/) Stay updated on the latest cannabis industry developments and law enforcement news from June 2026, providing clinical commentary and market insights. [Read More](https://cedclinic.com/cannabis-news-mix-june-2026-clinical-commentary/) [New Hampshire House Passes Scaled-Back Psilocybin Bill, While Rejecting Measure To …](https://cedclinic.com/psilocybin-policy-developments-new-hampshire-bill/) Explore recent legislative changes in psilocybin policy that may impact cannabis and psychedelic regulatory landscapes relevant to clinicians. [Learn More](https://cedclinic.com/psilocybin-policy-developments-new-hampshire-bill/) Hemp Gummies For Pain: The Best Natural Remedies For 2024 – Fathom Journal Discover natural hemp gummy remedies for pain management and their clinical relevance, complementing cannabis product discussions. Explore Now ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).